 |
Actavis manufacturing enjoined at three US sites
Monday 5 January 2009
Actavis has agreed to a consent decree with the US government barring it from manufacturing and distributing drug products at three Actavis Totowa facilities in New Jersey until they demonstrate compliance with good manufacturing practice requirements.
Latest News
Ferring's degarelix gets US approval
Ferring Pharmaceuticals' novel prostate cancer drug degarelix has been granted marketing approval by the US FDA for the treatment of patients with advanced hormone-dependent prostate cancer.
Monday 5 January 2009
US FDA misses user fee date for Novartis's Coartem
The December 26th user fee date for Novartis's combination antimalarial Coartem (artemether plus lumefantrine) has passed without US FDA action.
Monday 5 January 2009
A higher dose nicotine patch, Nicorette Invisipatch, launched in the UK
For those contemplating a New Year resolution to quit smoking, McNeil Products (Johnson & Johnson) has just the thing: it is introducing a higher dose, 25mg nicotine patch, Nicorette Invisipatch, in the UK in January.
Monday 5 January 2009
Spanish health ministry to invest in R&D
Spain's health ministry is aiming to boost biomedical and technological research through investments worth €45 million over the next four years.
Monday 5 January 2009
More News
Most Read
- Roche snaps up more biotech firms
- 2008 Scrip Awards celebrate industry's achievements
- Omeros appoints David Mann to Board
- Yondelis to be filed for ovarian cancer after Phase III success
- Amgen's denosumab succeeds in key osteoporosis trial
- Elan and Wyeth's Alzheimer's hope fails to impress
- BMS makes $4.5 billion bid for ImClone Systems
Features & Analysis
MolMed reveals secret to IPO success
In a year in which the number of successful biotech IPOs fell to just three, it is hard to understand how and why even those few triumphant companies managed to raise funds in such harsh economic conditions. However, Dr Claudio Bordignon, the CEO of MolMed who oversaw the Italian biotech's €56.2 million IPO in March, recently told Scrip that the company's success came as a result of three simple factors...
Commentary - 5 January 2009
Scrip stock tracker - November 2008
November brought with it more turmoil on the financial markets. Some hoped that as we limped towards the end of 2008, the end of the beginning might be in sight. With many major economies now in recession, in this Stock Tracker for November US reporter Christopher Spillane throws some light on how these events were trickling down to the life sciences.
Stock tracker - November 2008
Japan pharma takes its place in the global market
How Japanese companies face new challenges will determine the future size and shape of their role within the global industry. Dr Michael Jones surveys changes over the past decade and analyses the current corporate and regulatory environment
Executive Briefing - Vol 1 No 10 December 2008
Senior managers need fresh skills and solid experience
Pharma’s development leaders need to have the capacity to fall in love with their molecules, and the courage to demand a divorce should the circumstances warrant it, say Dr Stevo Knezevic and Dr Peter Woods
Market Insight - 23 December 2008
More Analysis
Blog
Merck & Co underlines pharma’s resilience to recession
The news that grabbed the headlines last week was Merck & Co’s aim to lead generic biologics. As it stands, Merck could be the first US brand name drug company to enter the generic biologics market...
Read More
Posted 18/12/2008 15:59:45 PM
by Christopher Spillane,
Reporter
The 'truth drug'
The Indian authorities are reported to be using a so-called ‘truth drug’ on the man arrested on suspicion of involvement in the recent atrocities in Mumbai.
Read More
Posted 11/12/2008 17:12:00 PM
by Dr Peter Charlish,
Analyst
About Scrip
Scrip World Pharmaceutical News provides you with high quality news coverage of pharma and biotech and also gives you strategic data and analysis.
Benefits include:
›› Daily email headlines
›› Searchable news
archive
›› Weekly copies of Scrip
›› Bespoke Scrip supplements
›› Plus the Scrip Yearbook
and Scrip League Tables
Scrip Awards 2008
The best and brightest of the pharmaceutical and biotech industries were celebrated at a glittering ceremony in London at the 2008 Scrip Awards.
Read the full story
Scrip Directory
Scrip Directory 2008
Search over 20,000 international contacts and access potential business opportunities
© Informa plc. All rights reserved. This site is owned and operated by Informa plc ("Informa") whose registered office is
Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36
